Drug · DIN 02420864
ABILIFY MAINTENA
200 MG/ML AFTER RECONSTITUTION. KIT CONTAINS: A) SYRINGE AND B) DILUENT
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since March 27, 2014; first marketed March 27, 2014.
- Drug Identification Number (DIN)
- 02420864
- Company (DIN owner)
- Otsuka Pharmaceutical Co LtdChiyoda-Ku Tokyo, --, Japan
- Schedule
- Prescription
- Dosage form
- Kit; Powder For Suspension (Sustained-Release
- Route
- Intramuscular
- Therapeutic class (ATC)
- Aripiprazole N05AX12
- Class
- Human
- Record last updated
- September 21, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ARIPIPRAZOLE | 300 MG | VIAL |
Notices of Compliance
Health Canada approvals that name this DIN.
- February 10, 2014: NOC 15223New Drug Submission (NDS)
Other DINs named ABILIFY MAINTENA
- DIN 02420872 · Marketed
- DIN 02445018 · Approved
- DIN 02445026 · Approved